REVA Medical (OTC:RVALL) launches its direct selling activities supporting its Fantom drug-eluting coronary scaffold after Boston Scientific allowed its exclusive right to negotiate for distribution to expire as specified under their 2007 agreement. The latter’s election window was triggered earlier this year when REVA delivered positive clinical data supporting the performance of the device.
